Dermatology Times
CLINICAL INSIGHTS THAT EXPAND EXPERTISE AND ADVANCE PRACTICE

Volume 38, Number 12 | December 2017

ATOPIC DERMATITIS in 2018

Pipeline expands with new target therapies

ANDREW BOWSER | Staff Correspondent

T he future of biologic treatments for atopic dermatitis may be quite diverse. While the 2017 approval of dupilumab (Dupixent/Regeneron) represents the first biologic for atopic dermatitis (AD), 2018 may bring news on a variety of other potential biologics that are currently under investigation.

The developments are part of a growing movement toward the use of targeted therapies for AD, writes Nupur Patel, MS, and Lindsay C. Strowd, M.D., in a recent article published in Advances in Experimental Medicine and Biology.

The emerging agents in atopic dermatitis include IL-4, IL-13, IgE, B-cells, IL-5, IL-31, JAK-STAT, SYK, IL-6, PDE-4, IL-12, IL-17, IL-22, IL-23, H4R, NR1, kOR, TSLP, PPAR-γ, and DGLA. In some cases, clinical trials have shown statistically significant improvements in clinical severity scores and patient-reported outcomes. In other cases, safety profiles are good, but many of these agents are in early trials.

“Our improved understanding about the mechanism for development of atopic dermatitis is leading to an expanding pipeline of new and more targeted treatment interventions,” according to Amy S. Paller, M.D., writing in the September issue of the Journal of Allergy and Clinical Immunology.

TARGETING IL-13
Dupilumab is a human monoclonal IgG4 antibody that inhibits IL-4 and IL-13 by binding

BUSINESS PLANNING

A realistic budget is one key to practice success

BOB KRONEMYER | Staff Correspondent

W hen it comes to financial planning, a realistic budget is key for a dermatologic practice. “Many of us in practice have zero background in business training,” says Sarah Jackson, M.D., of Audubon Dermatology in New Orleans. “Plus, I think that many dermatologists skip some of the basic things they should be doing—like a budget for financial planning.”

Dr. Jackson points out that a budget is more than spreadsheet. It’s a plan.

“It’s a plan to help you spend less than you earn. When you start, you need to look at real numbers. For an ongoing business, this entails reviewing past numbers and looking for areas of concern. In other words, focus on areas where you think you can spend less and areas where you think you can earn more,” she says.

A budget should allow a practice to have less anxiety and more control over what happens during a calendar year.

“It is not necessarily just about making more money. It may be seeing a different type of patient or having more vacation or making money from a procedure that up to now has been unprofitable,” Dr. Jackson says.

Creating a budget involves being thoughtful about “what you want to do more of and what you want to do less of,” she says.

MORE IN THIS ISSUE

- Clinical 16
  Plaque psoriasis
Summary of reports from American College of Rheumatology.

- Cosmetic 35
  Filler techniques
Experts share insights on the use of cannulas vs. needles.

- Oncology 48
  Squamous cell carcinoma
Guide to ID at-risk patients.

- Business 62
  Telemedicine
Legality varies among states.
Cannula use pearls
Experts share techniques that achieve great results

November 16, 2017
By John Jesitus

Choosing between a needle or cannula for filler injections is largely a matter of individual preference, said live-injection experts at The Cosmetic Bootcamp (CBC) 2017. For safety and accuracy of filler placement, they chose cannulas for filling the lips, hands and periocular area.

Lip injections with hyaluronic acid

“When you’re dealing with a cannula, the key is to get the entrance where you want it,” says Timothy Greco, M.D., F.A.C.S. After performing a nerve block, he explains, “I usually go just a few millimeters lateral to the oral commissure,” first with a needle. He then inserts a 1.5 inch, 27-gauge cannula, tracking along the vermilion border to reach the center of the philtrum. “Then I usually place approximately 0.1 cc of Juvederm Ultra (hyaluronic acid/HA, Allergan) along the vermilion border.” He also uses Juvederm Ultra Plus (hyaluronic acid/HA with Lidocaine, Allergan) or Restylane Silk (hyaluronic acid/HA with 0.3% Lidocaine, Galderma) for lip injections.

Passing along the wet-dry border, Dr. Greco next inserts the cannula into the center of the central tubercle and places a similar amount of filler.

“If you take the lower lip and divide it in half, then take that half and divide it into thirds, usually that middle third is where the tubercle is. That’s also where the depressor labii inferioris inserts.”

Injecting a small aliquot of product here shapes the lower lip, Dr. Greco says. Lastly, he injects a small amount of product behind the lower lip mucosa to slightly evert the lower lip. Both submucosal injections of the upper and lower lip are done in front of the frenulum of the lip.

Hands with calcium hydroxylapatite

Mary P. Lupo, M.D., says she uses Radiesse (calcium hydroxylapatite/CaHA, Merz) off-label in the hands. “I hyper-blend with an equal amount of lidocaine with epinephrine” to achieve slight vasoconstriction, she says. She is a New Orleans-based dermatologist, clinical professor of dermatology at Tulane University School of Medicine and a CBC cofounder.

“I use a 25-gauge, 2-inch cannula,” she says. With the patient properly positioned, she lifts the hand up and injects between veins, which she has located using the AccuVein device (AccuVein Inc.). From one injection point at the central dorsal wrist, she employs a fanning technique, extending with the cannula toward the first knuckle of each finger, ultimately encompassing the entire dorsum of the hand.

In the pivotal trial of CaHA for hands, Dr. Lupo says, investigators used three or four Radiesse syringes total per patient. In her
practice, “I’ve never done more than two at one time — one in each hand. I don’t know if it’s because of the biostimulatory effect or another factor such as the trauma of the cannula — but I don’t find I need large volumes. It keeps the cost down” and avoids a sausage-like appearance.

After injecting the hands, she typically massages in a topical bruise product such as Cytoactive gel (Eclipse Aesthetics).

Then we have the patient sit on her hand to further distribute the material and decrease any swelling,” she says.

**Periocular area with HA**

The patient treated by José Raúl Montes, M.D., requested tear trough injections, but he says her problem was really in the retro orbicularis oculi fat (ROOF) pad. He is a San Juan, Puerto Rico-based oculoplastic surgeon and professor, Ophthalmology Department, University of Puerto Rico School of Medicine.

He chose a cannula to inject this area, he says, because it provides more accurate filler placement with less trauma than a needle.² Before inserting a needle in the lateral periorbital area to make an opening for a cannula, he located and marked a vein-free zone using the AccuVein device. He also marked the patient’s orbital rim — the superior, medial and lateral canthus — and inferior orbital rim.

“I’m going to stay in this platform to inject 0.1 cc of Volbella (HA, Allergan),” using his nondominant hand against the orbital rim for guidance, injecting right on the zygomaticus bone near the lateral corner of the eye. He placed several similar injections around the orbital rim, using his index finger as a barrier between the injection point and the eyeball, then gently massaged the filler.

When injecting the ROOF, he recommends taking a lateral approach with the cannula.

“Make sure that the ROOF has adequate projection, because you don’t want to flatten that whole area. You want to create some convexities and concavities, and the ROOF injection will give you that,” he says.

Next he injected Belotero Balance (HA, Merz Aesthetics) above the orbit using a 1-inch 27-gauge cannula. Here, Dr. Montes threads the cannula without disturbing veins into the supraperiosteal area, below the orbicularis muscle.

“The ideal site for injecting the ROOF is where the highest peak of the eyebrow turns to into the lateral eyebrow,” he says.

**Disclosures:** Dr. Lupo is a partner in The Cosmetic Bootcamp. Dr. Montes is a speaker, trainer and consultant for Allergan, Galderma, Merz Aesthetics and Valeant. Dr. Greco reports no relevant financial interests.

**References**
